Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis
Stopped early · Phase 2
Conditions studied: Primary Biliary Cholangitis
In brief
The purpose of this open-label, pilot, proof of concept study is to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in participants with primary biliary cholangitis (PBC).
Key facts
- Study ID
- NCT03155932
- Run by
- Arena Pharmaceuticals
- People needed
- 2
- Starts
- 2017-12-29
- Expected to finish
- 2019-01-31
- Last updated by the study team
- 2022-03-24
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Gastroenterology and Hepatology, UC Davis Medical Center — Sacramento, California, United States
- Baylor College of Medicine — Houston, Texas, United States
- Texas Liver Institute — San Antonio, Texas, United States
- Swedish Medical Center — Seattle, Washington, United States
- Royal Prince Alfred Hospital — Camperdown, New South Wales, Australia
- Sunshine Coast University Hospital — Birtinya, Queensland, Australia
- Alfred Health — Melbourne, Victoria, Australia
- Auckland City Hospital — Grafton, Auckland, New Zealand
- Christchurch Clinical Studies Trust — Christchurch, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.